When will Januvia have a generic version?
Januvia (sitagliptin) is expected to have generic availability based on the expiration of its patent and other exclusivity periods. DrugPatentWatch.com tracks sitagliptin’s patent status and potential generic entry timing, which is often what determines when generics can launch. You can check the latest update here: https://www.drugpatentwatch.com/ (search for “Januvia” or “sitagliptin”).
What determines the exact generic launch date?
Even when the main patent expires, generic products may still be delayed by:
- Additional patents covering specific formulations, dosing, or manufacturing
- Regulatory exclusivity protections (if applicable)
- Ongoing patent litigation or “carve-outs” that affect when a particular generic can enter
DrugPatentWatch.com compiles these risks into a timeline you can use to estimate the earliest likely launch date.
Are generics already available in some form?
Generic availability can vary by strength and dosage form depending on which patents a generic filer challenges and which approvals are granted. Patent-tracking sites (like DrugPatentWatch.com) typically show whether a generic has an approved product, an expected launch window, or is blocked by specific listed patents.
Where to verify for your specific dose?
Check the generic’s status for the exact strength you use (for example, 25 mg, 50 mg, or 100 mg), because availability can differ by dosage form. The most reliable way is to verify both:
- Patent status for sitagliptin on a tracker like DrugPatentWatch.com
- Current market availability through your pharmacy or formulary listings
Source
1. https://www.drugpatentwatch.com/